PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE 2023 OCALA EQUINE CONFERENCE IN OCALA, FLORIDA
January 17 2023 - 8:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an
emerging biomedical device company focused on the commercialization
of innovative medical devices and therapeutics for companion
animals today announced it will be exhibiting at the 2023 FAEP
Ocala Equine Conference from January 21st to January 22nd, 2023 at
the World Equestrian Center in Ocala, FL.
“We are looking forward to networking with the
experts and leaders in the equine industry and develop
relationships that will help drive forward our innovative
veterinary medical device for the treatment of osteoarthritis,
Spryng™, with OsteoCushion™ Technology” said John Lai, Chief
Executive Officer of PetVivo Holdings, Inc.
Spryng is an injectable veterinary medical
device comprised of millions of micronized extracellular matrix
particles, which are derived from natural components, including
collagen and elastin. OsteoCushion Technology provides both
reinforcing natural joint support to augment and/or reinforce
missing and damaged cartilage, as well as delivers natural
scaffolding to help address tissue defects. These attributes offer
a great solution to manage lameness and joint afflictions, such as
osteoarthritis, for companion animals in a simple in-clinic
administration.
For more information about PetVivo Holdings,
Inc. please contact info1@petvivo.com or visit
https://petvivo.com/
Conference Details:
2023 Ocala Equine Conference
Booth #: 15
Dates:
Saturday, January 21, 2023 9:40am – 5:40pm
Sunday, January 22, 2023 9:40am – 1:10pm
Location: World Equestrian Center, Exposition
Center 1
About PetVivo
Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products at
various stages of development and/or commercialization for the
treatment of animals and people. A portfolio of nineteen patents
protects the Company's biomaterials, products, production processes
and methods of use. The Company’s lead product SPRYNG™ with
OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email:
info1@petvivo.com(952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024